Free Trial
NASDAQ:OBIO

Orchestra BioMed Q4 2023 Earnings Report

Orchestra BioMed logo
$2.46 +0.04 (+1.45%)
Closing price 05/7/2025 03:59 PM Eastern
Extended Trading
$2.54 +0.08 (+3.26%)
As of 05/7/2025 07:49 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Orchestra BioMed EPS Results

Actual EPS
-$0.37
Consensus EPS
-$0.38
Beat/Miss
Beat by +$0.01
One Year Ago EPS
N/A

Orchestra BioMed Revenue Results

Actual Revenue
$0.26 million
Expected Revenue
$1.00 million
Beat/Miss
Missed by -$740.00 thousand
YoY Revenue Growth
N/A

Orchestra BioMed Announcement Details

Quarter
Q4 2023
Time
N/A
Conference Call Date
Wednesday, March 27, 2024
Conference Call Time
8:00AM ET

Upcoming Earnings

Orchestra BioMed's Q1 2025 earnings is scheduled for Monday, May 12, 2025, with a conference call scheduled at 7:00 AM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Orchestra BioMed Earnings Headlines

Trump wipes out trillions overnight…
Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out nearly $5 trillion in wealth from the S&P 500 and $6.4 trillion from the Dow Jones… Not to mention the countless trillions of dollars lost in every market around the world… leaving the major political powers scrambling in fear of Trump’s next move.
See More Orchestra BioMed Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Orchestra BioMed? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Orchestra BioMed and other key companies, straight to your email.

About Orchestra BioMed

Orchestra BioMed (NASDAQ:OBIO) operates as a biomedical innovation company. The company's flagship product candidates include BackBeat Cardiac Neuromodulation Therapy (CNT) for the treatment of hypertension (HTN); and Virtue Sirolimus AngioInfusion Balloon (SAB) for the treatment of atherosclerotic artery disease. Its products also comprise FreeHold devices and minimally invasive surgery devices. The company has a collaboration agreement with Medtronic, Inc. for the development and commercialization of BackBeat CNT for the treatment of HTN in patients indicated for a cardiac pacemaker; and a strategic collaboration with Terumo Medical Corporation for the development and commercialization of Virtue SAB for the treatment of coronary and peripheral artery disease. Orchestra BioMed Holdings, Inc. is based in New Hope, Pennsylvania.

View Orchestra BioMed Profile

More Earnings Resources from MarketBeat